使用专用聚合物X射线造影剂的微血管断层成像
Tomographic imaging of microvasculature with a purpose-designed, polymeric X-ray contrast agent
摘要:
微血管系统的成像主要使用X射线造影剂进行,这是由于与具有相位对比能力的设备相比,吸收对比实验室源microCT的广泛可用性。然而,用于血管造影术的标准商业造影剂不适合于离体高分辨率成像,因为它们是能够在几分钟内扩散通过血管壁的小分子化合物。另一方面,大的基于纳米颗粒的血池造影剂表现出聚集的问题,导致最小血管中的堵塞。因此,尽管需要大量的训练和优化来适当地灌注粘性化合物,但是用固化塑料树脂注射仍然是微血管成像的黄金标准。即使进行了优化,频繁的气体和水夹杂物通常也会导致容器段中断。由于缺乏合适的化合物,我们开发了聚合物,交叉X射线造影剂XlinCA。作为水溶性有机分子,聚集和夹杂物是固有避免的。高分子量使其即使在肾脏过滤系统的高度有孔血管系统中也能保留。它可以使用组织固定方案中使用的相同醛进行共价交联,从而产生稳定和永久的造影剂。这些特性使我们能够在6至12个月大的C57 BL/6 J小鼠中对整个小鼠和单个器官进行成像,而不需要对注射速率和压力进行冗长的优化,同时与基于树脂的血管铸型相比,血管系统的填充得到了极大的改善。这项工作的目的是阐明的原理,过程和挑战,在创建这个最近开发的造影剂。
英文摘要:
Imaging of microvasculature is primarily performed with X-ray contrast agents, owing to the wide availability of absorption-contrast laboratory source microCT compared to phase contrast capable devices. Standard commercial contrast agents used in angiography are not suitable for high-resolution imaging ex vivo, however, as they are small molecular compounds capable of diffusing through blood vessel walls within minutes. Large nanoparticle-based blood pool contrast agents on the other hand exhibit problems with aggregation, resulting in clogging in the smallest blood vessels. Injection with solidifying plastic resins has, therefore, remained the gold standard for microvascular imaging, despite the considerable amount of training and optimization needed to properly perfuse the viscous compounds. Even with optimization, frequent gas and water inclusions commonly result in interrupted vessel segments. This lack of suitable compounds has led us to develop the polymeric, cross-linkable X-ray contrast agent XlinCA. As a water-soluble organic molecule, aggregation and inclusions are inherently avoided. High molecular weight allows it to be retained even in the highly fenestrated vasculature of the kidney filtration system. It can be covalently crosslinked using the same aldehydes used in tissue fixation protocols, leading to stable and permanent contrast. These properties allowed us to image whole mice and individual organs in 6 to 12-month-old C57BL/6J mice without requiring lengthy optimizations of injection rates and pressures, while at the same time achieving greatly improved filling of the vasculature compared to resin-based vascular casting. This work aims at illuminating the rationales, processes and challenges involved in creating this recently developed contrast agent.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。